

Benign Prostatic Hyperplasia Treatment Market by Type [Drug (Alpha Blockers(Tamsulosin, Doxazosin), 5-Alpha Reductase Inhibitors (Finasteride, Dutasteride), Surgical Treatment (TURP, TUMT, TUNA)], End User (Hospitals) - Global Forecast to 2026

<https://marketpublishers.com/r/B1778595D744EN.html>

Date: February 2021

Pages: 154

Price: US\$ 4,950.00 (Single User License)

ID: B1778595D744EN

Abstracts

The global benign prostatic hyperplasia treatment market is projected to reach USD 14.1 billion by 2026 from USD 10.8 billion in 2021, at a CAGR of 5.3% from 2021 to 2026. The growth of this market is driven owing to the increasing prevalence of benign prostatic hyperplasia, the rising preference for minimally invasive surgeries, increasing obesity rate, and investments, funds, and grants for research in the field of BPH treatment. Also, the emerging markets and promising product pipeline is anticipated to offer an opportunity for the growth of the market during the forecast period.

“Drug treatment is expected to hold the largest share of the benign prostatic hyperplasia treatment market, by type in 2021.”

Based on the type, the BPH treatment market is segmented into drug treatment and surgical treatment. Drug treatment is the largest and the fastest-growing segment in this market. This can primarily be attributed to the use of medications as the first line of treatment among men with mild to moderate symptoms of BPH.

“Home healthcare is expected to hold the largest share of the benign prostatic hyperplasia treatment market, in 2021.”

Based on the end user, the market is segmented into home healthcare and hospitals & clinics. In 2019, home healthcare accounted for the largest share of this market, as most patients are prescribed medications over surgery. Patients are also advised to

continue taking medications for a few weeks post-surgery and may even require catheters for a few days. As a result, the emphasis in his market is skewed toward home healthcare over hospital care.

“North America commanded the largest share of the benign prostatic hyperplasia treatment market in 2021.”

On the basis of region, the benign prostatic hyperplasia treatment market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. In 2019, North America commanded the largest share of the benign prostatic hyperplasia treatment market. The large share of this market segment can be attributed to the rising geriatric and obese population and the availability of research funding are the major factors driving the market growth. Initiatives by key players are also expected to contribute to the market.

Breakdown of supply-side primary interviews, by company type, designation, and region:

By Company Type: Tier 1 (20%) , Tier 2 (45%), and Tier 3 (35%)

By Designation: C-level (30%), Director-level (20%), and Others (50%)

By Region: North America (33%), Europe (24%), AsiaPacific (27%), and Rest of the World (16%)

The some of the major players operating in this market are GlaxoSmithKline plc. (UK), Astellas Pharma Inc. (Japan), Merck & Co., Inc. (US), Eli Lilly and Company (US), and Teleflex Incorporated (US).

List of Companies Profiled in the Report

Boston Scientific Corporation (US)

Coloplast Group (Denmark)

Teleflex Incorporated (US)

Olympus Corporation (Japan)

GlaxoSmithKline PLC (UK)

Eli Lilly (US)

Pfizer, Inc. (US)

Abbott (US)

Asahi Kasei Corporation (Japan)

Merck & Co., Inc. (US)

Astellas Pharma Inc. (Japan)

Allergan plc (Ireland)

Alembic (India)

IPG Photonics Corporation (US)

Richard Wolf GmbH (Germany)

Unilab, Inc. (Philippines)

Pharex Health Corporation (Philippines)

Biolitec AG (Austria)

Urologix, LLC (US)

Advin Health Care (India)

Medifocus, Inc. (Canada)

Asclepion Laser Technologies GmbH (Germany)

Pnn Medical A/S (Denmark)

Surgical Lasers Inc. (Canada)

Quanta Systems (Italy)

Allium Ltd. (Israel)

Lumenis Ltd. (Israel)

KARL STORZ SE & Co. KG (Germany)

SRS Medical (US).

Research Coverage

This report studies the benign prostatic hyperplasia treatment market based on type, end user and region. The report also analyzes factors (such as drivers, restraints, challenges, and opportunities) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total benign prostatic hyperplasia treatment market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:

The report provides insights on the following pointers:

Market Penetration: Comprehensive information on benign prostatic hyperplasia treatment offered by the top 29 players in the benign prostatic hyperplasia treatment market. The report analyzes the benign prostatic hyperplasia treatment market type, end user, and region.

Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various securement devices across key geographic regions.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the benign prostatic

hyperplasia treatment market

Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the benign prostatic hyperplasia treatment market

Frequently asked questions

What are the growth opportunities in the benign prostatic hyperplasia treatment market across major regions in the future?

Which type of drug is expected to hold the largest share in the benign prostatic hyperplasia treatment market?

Which form of surgery has been widely used in BPH treatment?

Which region has a well-developed benign prostatic hyperplasia treatment market?

What is the impact of COVID-19 on benign prostatic hyperplasia treatment market?

Contents

1 INTRODUCTION

- 1.1 OBJECTIVES OF THE STUDY
- 1.2 MARKET DEFINITION
 - 1.2.1 INCLUSIONS AND EXCLUSIONS
- 1.3 MARKET SCOPE
 - 1.3.1 MARKETS COVERED
 - 1.3.2 YEARS CONSIDERED FOR THE STUDY
- 1.4 CURRENCY
- 1.5 STAKEHOLDERS
- 1.6 LIMITATIONS OF THE CURRENT EDITION

2 RESEARCH METHODOLOGY

- 2.1 RESEARCH DATA
 - FIGURE 1 RESEARCH DESIGN
 - 2.1.1 SECONDARY DATA
 - 2.1.1.1 Key data from secondary sources
 - 2.1.2 PRIMARY DATA
 - FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
 - 2.1.2.1 Key data from primary sources
- 2.2 MARKET SIZE ESTIMATION
 - FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
 - 2.2.1 BOTTOM-UP APPROACH
 - FIGURE 4 BPH TREATMENT MARKET: BOTTOM-UP APPROACH
 - 2.2.2 GROWTH FORECAST
 - 2.2.3 TOP-DOWN APPROACH
 - FIGURE 5 BPH TREATMENT MARKET: TOP-DOWN APPROACH
- 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
 - FIGURE 6 DATA TRIANGULATION METHODOLOGY
- 2.4 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

- FIGURE 7 BPH TREATMENT MARKET, BY TYPE, 2021 VS. 2026 (USD BILLION)
- FIGURE 8 BPH TREATMENT MARKET, BY END USER, 2021 VS. 2026 (USD

BILLION)

FIGURE 9 BPH TREATMENT MARKET, BY REGION, 2021 VS. 2026 (USD BILLION)

4 PREMIUM INSIGHTS

4.1 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET OVERVIEW

FIGURE 10 INCREASING PREVALENCE OF BPH IS THE MAJOR FACTOR DRIVING THE GROWTH OF THIS MARKET

4.2 NORTH AMERICA: BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SHARE, BY TYPE (2020)

FIGURE 11 DRUG TREATMENT TO DOMINATE THE NORTH AMERICAN MARKET IN 2020

4.3 GEOGRAPHICAL SNAPSHOT OF THE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET

FIGURE 12 JAPAN TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD

5 MARKET OVERVIEW

5.1 INTRODUCTION

5.2 MARKET DYNAMICS

FIGURE 13 BPH TREATMENT MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

5.2.1 DRIVERS

5.2.1.1 Increasing prevalence of benign prostatic hyperplasia

FIGURE 14 SHARE OF MALE POPULATION AGED 65 AND ABOVE, GLOBAL (2015-2019)

5.2.1.2 Increasing obesity

5.2.1.3 Rising preference for minimally invasive surgeries

5.2.1.4 Investments, funds, and grants for research in BPH treatment

5.2.1.5 Availability of reimbursement for surgeries

TABLE 1 CPT CODES FOR BPH SURGERIES

5.2.2 RESTRAINTS

5.2.2.1 Side-effects associated with BPH medications

TABLE 2 SIDE-EFFECTS OF BPH DRUGS

5.2.3 OPPORTUNITIES

5.2.3.1 Emerging markets

5.2.3.2 Promising product pipeline

TABLE 3 PIPELINE DRUGS

5.2.4 CHALLENGES

5.2.4.1 Low awareness regarding prostate health among men

5.2.4.2 Product recalls in the BPH treatment market

TABLE 4 PRODUCT RECALLS IN THE BPH TREATMENT MARKET

5.3 VALUE CHAIN ANALYSIS

FIGURE 15 VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASE

5.4 SUPPLY CHAIN ANALYSIS

FIGURE 16 DIRECT DISTRIBUTION—THE PREFERRED STRATEGY OF PROMINENT COMPANIES

5.5 ECOSYSTEM ANALYSIS

FIGURE 17 ECOSYSTEM ANALYSIS OF THE PHARMACEUTICAL INDUSTRY

FIGURE 18 ECOSYSTEM ANALYSIS OF THE UROLOGY DEVICES MARKET

5.6 REGULATORY SCENARIO

5.6.1 PHARMACEUTICAL INDUSTRY

5.6.1.1 Regulatory requirements

5.6.1.1.1 EU regulations

5.6.1.1.2 US regulations

5.6.2 MEDICAL DEVICES INDUSTRY

TABLE 5 LIST OF REGULATORY AUTHORITIES

5.6.2.1 Regulatory requirements

5.6.2.1.1 EU regulations

5.6.2.1.2 US regulations

5.7 AVERAGE SELLING PRICE TREND

TABLE 6 AVERAGE SELLING PRICE OF BPH DRUGS

TABLE 7 AVERAGE SELLING PRICE OF BPH TREATMENT PROCEDURES

TABLE 8 AVERAGE SELLING PRICE OF DEVICES USED IN BPH TREATMENT PROCEDURES

5.8 TECHNOLOGY ANALYSIS

5.9 PESTLE ANALYSIS

5.10 COVID-19 IMPACT ANALYSIS ON THE BPH TREATMENT MARKET

5.11 EPIDEMIOLOGY OF BENIGN PROSTATIC HYPERPLASIA (2019)

TABLE 9 BPH: COUNTRY-WISE PREVALENCE, 2019

6 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY TYPE

6.1 INTRODUCTION

TABLE 10 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)

6.2 DRUG TREATMENT

TABLE 11 BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)

TABLE 12 BPH DRUG TREATMENT MARKET, BY REGION, 2018–2026 (USD MILLION)

6.2.1 ALPHA BLOCKERS

TABLE 13 BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 14 BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY REGION, 2018–2026 (USD MILLION)

6.2.1.1 Tamsulosin

6.2.1.1.1 Tamsulosin has been prescribed for BPH since 2000

TABLE 15 TAMSULOSIN MARKET, BY REGION, 2018–2026 (USD MILLION)

6.2.1.2 Silodosin

6.2.1.2.1 Benefits of silodosin and launch of generics support market growth

TABLE 16 SILODOSIN MARKET, BY REGION, 2018–2026 (USD MILLION)

6.2.1.3 Alfuzosin

6.2.1.3.1 Side-effects and fewer generic launches have hindered market growth to some extent

TABLE 17 ALFUZOSIN MARKET, BY REGION, 2018–2026 (USD MILLION)

6.2.1.4 Doxazosin

6.2.1.4.1 Doxazosin was introduced in 2005 and has seen many generic launches since

TABLE 18 DOXAZOSIN MARKET, BY REGION, 2018–2026 (USD MILLION)

6.2.1.5 Other alpha blockers

TABLE 19 OTHER ALPHA BLOCKERS MARKET, BY REGION, 2018–2026 (USD MILLION)

6.2.2 5-ALPHA REDUCTASE INHIBITORS

TABLE 20 BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 21 BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY REGION, 2018–2026 (USD MILLION)

6.2.2.1 Dutasteride

6.2.2.1.1 Availability of generics post-patent expiry support market growth

TABLE 22 DUTASTERIDE MARKET, BY REGION, 2018–2026 (USD MILLION)

6.2.2.2 Finasteride

6.2.2.2.1 Finasteride provides a range of benefits but is less effective than alpha blockers in improving LUTS

TABLE 23 FINASTERIDE MARKET, BY REGION, 2018–2026 (USD MILLION)

6.2.3 OTHER DRUG CLASSES

TABLE 24 OTHER BPH DRUG CLASSES MARKET, BY REGION, 2018–2026 (USD MILLION)

6.3 SURGICAL TREATMENT

TABLE 25 BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)

TABLE 26 BPH SURGICAL TREATMENT MARKET, BY REGION, 2018–2026 (USD MILLION)

6.3.1 TRANSURETHRAL RESECTION OF THE PROSTATE

6.3.1.1 TURP is the gold standard for BPH treatment

TABLE 27 BPH SURGICAL TREATMENT MARKET FOR TURP, BY REGION, 2018–2026 (USD MILLION)

6.3.2 LASER SURGERY

6.3.2.1 Evolution in lasers and high efficacy have supported the demand for laser surgery

TABLE 28 BPH SURGICAL TREATMENT MARKET FOR LASER SURGERY, BY REGION, 2018–2026 (USD MILLION)

6.3.3 TRANSURETHRAL MICROWAVE THERMOTHERAPY

6.3.3.1 TUMT has a lower risk of bleeding and requires no hospital stay, which has driven preference

TABLE 29 BPH SURGICAL TREATMENT MARKET FOR TUMT, BY REGION, 2018–2026 (USD MILLION)

6.3.4 UROLIFT THERAPY

6.3.4.1 Low rate of post-implantation surgical intervention indicates high effectiveness of UroLift and the potential for adoption

TABLE 30 BPH SURGICAL TREATMENT MARKET FOR UROLIFT THERAPY, BY REGION, 2018–2026 (USD MILLION)

6.3.5 TRANSURETHRAL NEEDLE ABLATION OF THE PROSTATE

6.3.5.1 Reimbursement coverage and growing preference for TUNA drive market growth

TABLE 31 BPH SURGICAL TREATMENT MARKET FOR TUNA, BY REGION, 2018–2026 (USD MILLION)

6.3.6 REZ?M THERAPY

6.3.6.1 The cost-effectiveness and efficacy of Rez?m water vapor therapy are driving demand for the procedure

TABLE 32 BPH SURGICAL TREATMENT MARKET FOR REZ?M THERAPY, BY REGION, 2018–2026 (USD MILLION)

6.3.7 PROSTATIC STENTING

6.3.7.1 Prostatic stenting is a temporary measure conducted under local anesthesia

TABLE 33 BPH SURGICAL TREATMENT MARKET FOR PROSTATIC STENTING, BY REGION, 2018–2026 (USD MILLION)

6.3.8 OTHER SURGERIES

TABLE 34 OTHER BPH SURGICAL TREATMENTS MARKET, BY REGION, 2018–2026 (USD MILLION)

7 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY END USER

7.1 INTRODUCTION

TABLE 35 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)

7.2 HOME HEALTHCARE

7.2.1 LARGE PATIENT POPULATION USING MEDICATIONS TO DRIVE THE GROWTH OF THE SEGMENT

TABLE 36 BPH TREATMENT MARKET FOR HOME HEALTHCARE, BY REGION, 2018–2026 (USD MILLION)

7.3 HOSPITALS & CLINICS

7.3.1 RISING PREFERENCE FOR MINIMALLY INVASIVE SURGERIES TO DRIVE THE GROWTH OF THE SEGMENT

TABLE 37 BPH TREATMENT MARKET FOR HOSPITALS & CLINICS, BY REGION, 2018–2026 (USD MILLION)

8 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY REGION

8.1 INTRODUCTION

TABLE 38 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY REGION, 2018–2026 (USD MILLION)

8.2 NORTH AMERICA

FIGURE 19 NORTH AMERICA: BPH TREATMENT MARKET SNAPSHOT

TABLE 39 NORTH AMERICA: BPH TREATMENT MARKET, BY COUNTRY, 2018–2026 (USD MILLION)

TABLE 40 NORTH AMERICA: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)

TABLE 41 NORTH AMERICA: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)

TABLE 42 NORTH AMERICA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018, 2018–2026 (USD MILLION)

TABLE 43 NORTH AMERICA: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 44 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)

TABLE 45 NORTH AMERICA: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)

8.2.1 US

8.2.1.1 The US holds the largest share of the North American market

TABLE 46 US: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)

TABLE 47 US: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)

TABLE 48 US: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 49 US: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 50 US: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)

TABLE 51 US: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)

8.2.2 CANADA

8.2.2.1 Rising geriatric population and product approvals to support market growth

TABLE 52 CANADA: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)

TABLE 53 CANADA: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)

TABLE 54 CANADA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 55 CANADA: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 56 CANADA: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)

TABLE 57 CANADA: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)

8.3 EUROPE

TABLE 58 EUROPE: BPH TREATMENT MARKET, BY COUNTRY, 2018–2025 (USD MILLION)

TABLE 59 EUROPE: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)

TABLE 60 EUROPE: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)

TABLE 61 EUROPE: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS,

BY TYPE, 2018–2026 (USD MILLION)

TABLE 62 EUROPE: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 63 EUROPE: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)

TABLE 64 EUROPE: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)

8.3.1 GERMANY

8.3.1.1 Increasing healthcare expenditure to support German market growth

TABLE 65 GERMANY: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)

TABLE 66 GERMANY: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)

TABLE 67 GERMANY: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018, 2018–2026 (USD MILLION)

TABLE 68 GERMANY: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 69 GERMANY: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)

TABLE 70 GERMANY: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)

8.3.2 UK

8.3.2.1 Availability of innovative treatment options to drive the market in the UK

TABLE 71 UK: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)

TABLE 72 UK: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)

TABLE 73 UK: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 74 UK: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 75 UK: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)

TABLE 76 UK: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)

8.3.3 FRANCE

8.3.3.1 Rising geriatric population to accelerate the growth of the market

TABLE 77 FRANCE: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)

TABLE 78 FRANCE: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026

(USD MILLION)

TABLE 79 FRANCE: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 80 FRANCE: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 81 FRANCE: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)

TABLE 82 FRANCE: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)

8.3.4 REST OF EUROPE

TABLE 83 ROE: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)

TABLE 84 ROE: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)

TABLE 85 ROE: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018, 2018–2026 (USD MILLION)

TABLE 86 ROE: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 87 ROE: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)

TABLE 88 ROE: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)

8.4 ASIA PACIFIC

FIGURE 20 ASIA PACIFIC: BPH TREATMENT MARKET SNAPSHOT

TABLE 89 ASIA PACIFIC: BPH TREATMENT MARKET, BY COUNTRY, 2018–2026 (USD MILLION)

TABLE 90 ASIA PACIFIC: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)

TABLE 91 ASIA PACIFIC: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)

TABLE 92 ASIA PACIFIC: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018, 2018–2026 (USD MILLION)

TABLE 93 ASIA PACIFIC: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 94 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)

TABLE 95 ASIA PACIFIC: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)

8.4.1 JAPAN

8.4.1.1 Japan holds the largest share of the APAC market

TABLE 96 JAPAN: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)

TABLE 97 JAPAN: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)

TABLE 98 JAPAN: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018, 2018–2026 (USD MILLION)

TABLE 99 JAPAN: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 100 JAPAN: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)

TABLE 101 JAPAN: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)

8.4.2 CHINA

8.4.2.1 Increasing obese population to support market growth

TABLE 102 CHINA: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)

TABLE 103 CHINA: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)

TABLE 104 CHINA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018, 2018–2026 (USD MILLION)

TABLE 105 CHINA: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 106 CHINA: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)

TABLE 107 CHINA: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)

8.4.3 INDIA

8.4.3.1 Rising prevalence of obesity to accelerate market growth in India

TABLE 108 INDIA: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)

TABLE 109 INDIA: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)

TABLE 110 INDIA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018, 2018–2026 (USD MILLION)

TABLE 111 INDIA: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 112 INDIA: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)

TABLE 113 INDIA: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)

MILLION)

8.4.4 REST OF ASIA PACIFIC

TABLE 114 ROAPAC: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)

TABLE 115 ROAPAC: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)

TABLE 116 ROAPAC: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 117 ROAPAC: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 118 ROAPAC: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)

TABLE 119 ROAPAC: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)

8.5 REST OF THE WORLD

TABLE 120 ROW: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)

TABLE 121 ROW: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)

TABLE 122 ROW: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018, 2018–2026 (USD MILLION)

TABLE 123 ROW: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 124 ROW: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)

TABLE 125 ROW: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)

9 COMPETITIVE LANDSCAPE & COMPANY PROFILES

9.1 COMPETITIVE LANDSCAPE

9.1.1 OVERVIEW

FIGURE 21 KEY DEVELOPMENTS IN THE BPH TREATMENT MARKET, JANUARY 2017–JANUARY 2021

FIGURE 22 MARKET EVOLUTION FRAMEWORK: JANUARY 2017 TO JANUARY 2021

9.1.2 MARKET SHARE ANALYSIS, 2019

9.1.2.1 BPH Drug Treatment Market Share Analysis, 2019

FIGURE 23 BPH DRUG TREATMENT MARKET SHARE ANALYSIS, 2019

9.1.2.2 BPH Surgical Treatment Market Share Analysis, 2019

FIGURE 24 BPH SURGICAL TREATMENT MARKET SHARE ANALYSIS, 2019**9.1.3 COMPETITIVE SCENARIO**

9.1.3.1 Product launches and approvals

TABLE 126 KEY PRODUCT LAUNCHES & APPROVALS, JANUARY 2017?JANUARY 2021

9.1.3.2 Acquisitions

TABLE 127 KEY ACQUISITIONS, JANUARY 2017?JANUARY 2021

9.1.3.3 Agreements and collaborations

TABLE 128 KEY AGREEMENTS AND COLLABORATIONS, JANUARY 2017?JANUARY 2021

9.1.3.4 Expansions

TABLE 129 KEY EXPANSIONS, JANUARY 2017?JANUARY 2021

9.1.3.5 Other developments

TABLE 130 OTHER DEVELOPMENTS, JANUARY 2017?JANUARY 2021**9.1.4 COMPANY EVALUATION MATRIX**

9.1.4.1 Stars

9.1.4.2 Emerging Leaders

9.1.4.3 Pervasive Companies

9.1.4.4 Participants

FIGURE 25 BPH TREATMENT MARKET: COMPANY EVALUATION MATRIX, 2019**9.1.5 COMPETITIVE LEADERSHIP MAPPING (START-UPS AND SMES)**

9.1.5.1 Progressive Companies

9.1.5.2 Starting Blocks

9.1.5.3 Responsive Companies

9.1.5.4 Dynamic Companies

FIGURE 26 BPH TREATMENT MARKET: VENDOR DIVE MATRIX FOR SMES AND START-UPS, 2019**9.2 COMPANY PROFILES**

(Business overview, Products offered, Recent Developments, MNM view)*

9.2.1 GLAXOSMITHKLINE**FIGURE 27 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2019)****9.2.2 ASTELLAS PHARMA****FIGURE 28 ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2019)****9.2.3 MERCK****FIGURE 29 MERCK: COMPANY SNAPSHOT (2019)****9.2.4 ELI LILLY AND COMPANY****FIGURE 30 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2019)****9.2.5 TELEFLEX INCORPORATED****FIGURE 31 TELEFLEX INCORPORATED: COMPANY SNAPSHOT (2019)**

9.2.6 ABBOTT LABORATORIES

FIGURE 32 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2019)

9.2.7 BOSTON SCIENTIFIC CORPORATION

FIGURE 33 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2019)

9.2.8 PFIZER

FIGURE 34 PFIZER: COMPANY SNAPSHOT (2019)

9.2.9 OLYMPUS CORPORATION

FIGURE 35 OLYMPUS CORPORATION: COMPANY SNAPSHOT (2019)

9.2.10 ALEMBIC

FIGURE 36 ALEMBIC: COMPANY SNAPSHOT (2019)

9.2.11 ASAHI KASEI CORPORATION

FIGURE 37 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2019)

9.2.12 ALLERGAN

FIGURE 38 ALLERGAN: COMPANY SNAPSHOT (2019)

9.2.13 COLOPLAST GROUP

FIGURE 39 COLOPLAST GROUP: COMPANY SNAPSHOT (2020)

9.2.14 IPG PHOTONICS CORPORATION

FIGURE 40 IPG PHOTONICS CORPORATION: COMPANY SNAPSHOT (2019)

9.2.15 KARL STORZ SE & CO. KG

9.2.16 RICHARD WOLF GMBH

9.2.17 LUMENIS LTD.

9.2.18 UNILAB, INC.

9.2.19 PHAREX HEALTH CORP

9.2.20 BIOLITEC AG

9.2.21 UROLOGIX, LLC.

9.2.22 ADVIN HEALTH CARE

9.2.23 MEDIFOCUS INC.

9.2.24 ASCLEPION LASER TECHNOLOGIES GMBH

9.2.25 PNN MEDICAL A/S

9.2.26 SURGICAL LASERS INC.

9.2.27 QUANTA SYSTEM

9.2.28 ALLIUM LTD

9.2.29 SRS MEDICAL

*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

10 APPENDIX

10.1 INDUSTRY INSIGHTS

10.2 DISCUSSION GUIDE

10.3 KNOWLEDGE STORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL

10.4 AVAILABLE CUSTOMIZATIONS

10.5 RELATED REPORTS

10.6 AUTHOR DETAILS

I would like to order

Product name: Benign Prostatic Hyperplasia Treatment Market by Type [Drug (Alpha Blockers(Tamsulosin, Doxazosin), 5-Alpha Reductase Inhibitors (Finasteride, Dutasteride), Surgical Treatment (TURP, TUMT, TUNA), End User (Hospitals) - Global Forecast to 2026

Product link: <https://marketpublishers.com/r/B1778595D744EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B1778595D744EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970